Viewing Study NCT06504459

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 2:50 PM

Ignite Modification Date: 2026-04-13 @ 5:37 PM

Study NCT ID: NCT06504459

Status: RECRUITING

Last Update Posted: 2025-08-27

First Post: 2024-07-11

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Sponsor: OHSU Knight Cancer Institute

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module